Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CNTO 328 (Siltuximab) in Healthy Subjects
NCT02074800Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2008
- Primary completion
- Jun 2009
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of siltuximab in Multicentric Castleman disease (MCD) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Number of participants with adverse events at Day 199, Maximum observed serum concentration at Day 85 and 1 more. Started Jun 2008; status: completed.
02
Drugs
siltuximab
03
Conditions
Multicentric Castleman disease (MCD)
Beyond the preview
Go deeper on NCT02074800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02074800.